Alnylam Pharmaceuticals Inc.’s stock ALNY jumped nearly 40% premarket on Monday after the company released results of a late-stage trial for a heart drug that analysts see competing with a key ...

Walter Mercado, a native of the Philippines, remembers the day doctors told him that a heart defect could claim his infant son’s life before his first birthday. Francis Steven was only 3 days ...

The trial involved patients with transthyretin amyloidosis with cardiomyopathy, or ATTR-CM, a debilitating condition that causes the heart to stiffen and limits its ability to pump blood.